Health Benefit Costs and Absenteeism Due to Insomnia From the Employer’s Perspective: A Retrospective, Case-Control, Database Study
J Clin Psychiatry 2009;70(8):1098-1104
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: To objectively assess the economic impact of insomnia on direct medical and prescription costs and indirect absence-related salary replacement costs and on absences and to compare the prevalence and costs of comorbidities in employees with and without insomnia.
Method: A retrospective analysis was performed on employee data from the Human Capital Management Services Research Reference Database (January 2001–September 2007). Employees were identified as having insomnia (ICD-9 criteria) based on history of receiving medications used to treat insomnia or physician’s diagnosis of insomnia. Control employees had no history of medications used to treat insomnia and no insomnia diagnosis. Annual costs and number of absences were compared using 2-part regression models, controlling for demographics, job information, geographic region, comorbid disorders, and the Charlson Comorbidity Index score. Comorbidity prevalence, costs, and services were compared.
Results: Data were collected for 299,188
employees (17,230 employees with insomnia
and 281,958 control employees). Annual mean incremental costs were $2,053 greater (in total)
for employees with insomnia compared with controls (specific increments: medical $751, drug
$735, sick leave $208, short-term disability $179, long-term disability $10, and workers’ compensation $170). Employees with insomnia missed a mean of 3.10 more workdays annually than those without insomnia. Nearly all comorbid conditions were more prevalent, were more costly, and resulted in a greater utilization of services in employees with insomnia compared to those without. All of the above comparisons were significant (P < .05).
Conclusion: Insomnia was associated with increased costs, greater absenteeism, and an increased number of comorbid conditions in an employed population. Consistent with other analyses based on these data, the study estimated the annual cost of insomnia in the US civilian labor force to be approximately $15.0–17.7 billion
Submitted: October 19, 2007; accepted August 28, 2008.
Corresponding author: Nathan L. Kleinman, PhD, HCMS Group, 1800 Carey Ave, Suite 300, Cheyenne, WY 82001